Stock Watch: The Transatlantic Asymmetries Of Generic Drugs
Many Small-Molecule Generic Drug Dynamics Contrast Biosimilars
Executive Summary
Investors love an opportunity to invest in a recovery play after the disclosure of bad news but, having lived in recent years under a succession of clouds, will generic drug companies begin to see biosimilars resurrect their sales growth?